Cencora said revenue increased by $6.4 billion (8.7%) from the prior year quarter and $22.7 billion (10.6%) for the 9 months ended, respectively. The company cited unit volume growth and increased sales of GLP-GLP-1 products of $1.4 billion (18.6%) from the prior year quarter as factors driving U.S. Healthcare Solutions segment growth.

1. 01

   Cencora said revenue increased by $6.4 billion (8.7%) from the prior year quarter and $22.7 billion (10.6%) for the 9 months ended, respectively. The company cited unit volume growth and increased sales of GLP-GLP-1 products of $1.4 billion (18.6%) from the prior year quarter as factors driving U.S. Healthcare Solutions segment growth.

2. 02

   Cencora said gross profit increased by $496.3 million (20.6%) for the quarter and $1,107.4 million (14.9%) for the 9 months ended, compared to the prior year periods. The company cited increases in gross profit in both reportable segments and a LIFO credit in the current quarter as factors driving the quarter increase, offset in part by lower gains from antitrust litigation settlements.

3. 03

   Cencora said net interest expense increased by $50.5 million (161.1%) for the quarter and $77.7 million (57.1%) for the 9 months ended, compared to the prior year periods. The company cited the issuance of $1.8 billion of senior notes in December 2024 and borrowings of $1.5 billion of variable-rate term loan in January 2025 to finance a portion of the RCA acquisition as factors for the increase.

4. 04

   Cencora said it generated $741.7 million of cash from operating activities during the 9 months ended June 30, 2025, compared to $2.5 billion in the prior year period. The company cited changes in working capital accounts as a factor in the decrease and said investing activities included $3.9 billion used for the RCA acquisition during the same period.

Key figures

Quarter ended June 30, 2025

Revenue

$80.7B

Operating income

$868M

Net income

$687M

EPS

$3.52

Gross profit

$2.9B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.